Adherex Technologies (NASDAQ:FENC) Announces Quarterly Earnings Results

Adherex Technologies (NASDAQ:FENC) issued its earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03, Zacks reports. Adherex Technologies had a negative return on equity of 43.87% and a negative net margin of 17.12%.

Here are the key takeaways from Adherex Technologies’ conference call:

• PEDMARK net product sales rose 78% year over year to $17.1 million in Q2 2026, marking the company’s seventh consecutive quarter of growth. Non-GAAP adjusted EBITDA improved to $2.8 million from a $1.2 million loss a year ago.
• Commercial momentum accelerated, with Q2 demand up double digits sequentially, record patient enrollments and infusions, and a 280% increase in sales calls. July produced all-time highs for completed infusions, new enrollments, active patients, and new customers, while the expanded sales force now reaches roughly 5,000 targets.
• Medical and clinical efforts are expanding, including three actively accruing investigator-sponsored studies and an upcoming oral presentation of Japan’s STS-J01 trial data at SIOP 2026. Management said maturing data could support future label expansions and stronger NCCN recommendations, while discussions with potential Japanese and Asia-Pacific partners continue.
• Operating expenses excluding stock-based compensation increased to approximately $13.6 million, driven largely by higher commercial headcount and marketing investments. Management expects cash to decline in Q3 due to customer collection cycles, although it anticipates positive cash generation in Q4 and year-end cash.

Adherex Technologies Price Performance

Shares of FENC stock traded up $1.02 during mid-day trading on Tuesday, hitting $11.96. The stock had a trading volume of 232,424 shares, compared to its average volume of 203,282. Adherex Technologies has a 12-month low of $5.65 and a 12-month high of $13.25. The firm’s 50-day moving average is $10.02 and its two-hundred day moving average is $8.51. The firm has a market capitalization of $419.42 million, a P/E ratio of -40.28 and a beta of 1.09.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC bought a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned approximately 0.05% of Adherex Technologies at the end of the most recent reporting period. Institutional investors own 55.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on FENC shares. Wall Street Zen raised shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 price objective on shares of Adherex Technologies in a research note on Thursday, April 16th. Zacks Research upgraded shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. HC Wainwright increased their target price on Adherex Technologies from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $15.40.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.